Women's Health Month: Understanding How Menopause Can Impact Your Sex Life, According to a Sex & Relationships Expert
LOS ANGELES--(BUSINESS WIRE)--During menopause, women undergo significant hormonal, physical, and emotional changes, many of which can have a direct impact on sexual health and relationships. These changes are natural, but they can also be challenging, especially when they go unspoken or unsupported. In recognition of Women's Health Month, Dr. Shannon Chavez, a renowned sex and relationships expert and licensed psychologist, is shedding light on how menopause affects intimacy, and why open conversations, education, and personalized care are essential for supporting women through this stage.
"Just like puberty, this is a hormonal milestone that requires education, compassion, and the right tools. With support, this stage of life can lead to deeper self-awareness, empowerment, and even better sex.'
'Menopause is not the end of your sex life—it's the beginning of a new chapter,' says Dr. Chavez. 'But it's a chapter that comes with changes that women deserve to understand and navigate with confidence. Just like puberty, this is a hormonal milestone that requires education, compassion, and the right tools. With support, this stage of life can lead to deeper self-awareness, empowerment, and even better sex.'
Below, Dr. Chavez shares key ways menopause can affect your sex life, as well as practical guidance for navigating these changes with confidence and care:
Hormonal Shifts Can Affect Desire: A decline in estrogen and testosterone levels during menopause can lead to a noticeable drop in libido. Many women find themselves feeling less interested in sex due to hormonal changes that are entirely natural. Desire can be rekindled with intentional practices like sensate focus, sexual mindfulness, and, when appropriate, bioidentical hormone therapy.
Vaginal Dryness and Discomfort: As estrogen levels drop, the vaginal walls may become thinner, dryer, and less elastic, making intercourse uncomfortable or even painful. Vaginal dryness is one of the most common symptoms of menopause. Luckily, over-the-counter vaginal moisturizers and lubricants can improve comfort and make intimacy pleasurable again. I recommend Replens Long-Lasting Vaginal Moisturizer and Replens Silky Smooth Personal Lubricant for effective relief.
Emotional and Psychological Changes: Menopause can also bring mood swings, anxiety, sleep disturbances, and body image concerns—all of which can influence how one feels about sex and intimacy. Self-compassion, therapy, mindfulness practices, and strong communication with a partner can help women reclaim pleasure and emotional connection.
Changes in Arousal: Many women notice it takes longer to become aroused or reach orgasm during and after menopause. This is due to changes in blood flow, nerve sensitivity, and lubrication. While this can be frustrating, Dr. Chavez emphasizes that slower arousal isn't something to fear or feel ashamed of. In fact, it can lead to more intentional and deeply satisfying intimacy when couples take the time to adapt their approach to pleasure.
'A satisfying sex life during and after menopause is absolutely possible, but it starts with education and honest communication,' says Dr. Chavez. 'The more you understand your body and talk openly with your partner and healthcare provider, the more empowered you'll feel to create the kind of intimacy that truly fulfills you.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options
CHICAGO--(BUSINESS WIRE)--Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious complications associated with advanced stages of the cancer. "This study represents a significant advancement in our understanding of how to treat brain metastases and leptomeningeal disease" - Dr. Matthias Preusser. Share The study was carried out to evaluate HER3-DXd in patients with metastatic breast cancer (mBC) and advanced non-small cell lung cancer (aNSCLC) with active brain metastases, and patients with leptomeningeal disease from solid tumors. This is an antibody-drug conjugate to target HER3, a protein receptor found on the surface of cancer cells in brain metastases. HER3-DXd is an investigational agent consisting of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC Technology payload causes tumor DNA damage, killing cancer cells within and surrounding the tumor microenvironment The study showed promising results, which were presented today in an oral session. Results from the leptomeningeal cohort have been simultaneously published in the renowned journal Nature Medicine due to its potential benefit in patients with a high unmet medical need. In patients with breast cancer and brain metastases, intracranial responses were observed across all breast cancer subtypes, including luminal, HER2-positive, and triple-negative. A NEW HOPE FOR DIFFICULT-TO-TREAT METASTASES 'This study represents a significant advancement in our understanding of how to treat brain metastases and leptomeningeal disease, and we are hopeful that our findings will pave the way for new, effective therapies for these patients,' stated Dr. Matthias Preusser, MD, Medical Oncologist and Head of the Clinical Division of Oncology, Medical University of Vienna and Principal Investigator of TUXEDO-3. Dr. Rupert Bartsch, MD, PhD, Consultant Hematology and Medical Oncology, Medical University of Vienna, added: 'Brain metastases and leptomeningeal disease represent severe complications in cancer, leading to increased morbidity and mortality, and HER3-DXd could be a promising therapeutic alternative for these patients.' MEDSIR's trial DEMETHER, an international, phase II trial exploring the maintenance of trastuzumab and pertuzumab following trastuzumab deruxtecan as induction treatment for HER2-positive recurrent metastatic breast cancer patients, was mentioned during today's Discussion of LBA1008. DEMETHER's strategy is to optimize the sequence to increase patients' progression free survival (PFS) while improving their quality of life. The relevance of this mention highlighted the ability of MEDSIR for anticipating patients' needs and designing strategical trials to keep on pushing the barriers of clinical research. MEDSIR active presence at the ASCO Annual Meeting 2025 reinforces its leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in cancer treatment, with the aim of not leaving any patient left behind.
Yahoo
2 hours ago
- Yahoo
eClinical Solutions to Lead Industry Discussions on Modernizing Clinical Trials at DIA 2025 and Series of Company Events This Summer
Global eClinical Connect events kick off this week, leading up to annual ENGAGE conference in the fall, as company continues to build innovative avenues to empower life sciences leaders BOSTON, June 04, 2025--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced its participation in several June events, including the DIA 2025 Global Annual Meeting, a leading life sciences event that brings together industry professionals to drive large-scale collaboration and transformation in the sector. With the company's commitment to supporting biopharma researchers in driving tomorrow's breakthroughs, eClinical is also hosting the eClinical Connect event series, including two events in Europe, creating additional global forums for industry experts to share insights and actionable strategies to tackle today's most pressing issues in the life sciences. DIA 2025 Global Annual Meeting Following years of industry and regulatory efforts to ensure inclusive and representative trials, including Diversity Action Plans, leaders are collaborating to make tangible progress on initiatives promoting clinical trial diversity. To support these efforts, eClinical Solutions will host a panel at DIA (June 15-19 in Washington, DC) titled "Techquity in Digital Trials: Tech, Data, and Operationalizing Equity in Clinical Research," which will explore how biopharma can leverage data foundations and technological advancements - including artificial intelligence (AI) and machine learning (ML) - to improve access and representation in clinical trials. eClinical Solutions' Katrina Rice, Chief Delivery Officer of Biometrics Services, will chair the panel and be joined by industry authorities including Patrick Gee, Patient Advocate, Founder and Chief Executive Hope Dealer at iAdvocate, Inc., Nicole Ward, Senior Product Manager, Business Insights and Technology at Bristol Myers Squibb, and Del Smith, CEO and Co-founder at Acclinate. The discussion will focus on critical areas where technology and analytics can help facilitate health equity advancement, outline concrete use cases where technology and data can support equitable clinical research, and detail non-technical success factors needed to wholly support data-driven technology. The conversation will take place June 18 between 1:45 pm - 2:45 pm ET. eClinical Connect In addition to its presence at this premier industry conference, the company will host three complimentary, global eClinical Connect events this month, which feature timely and informative panel discussions: eClinical Connect in Newton, Massachusetts, USA (June 4): The first event will focus on considerations for adopting risk-based approaches, which continue to be top of mind as regulatory demands increase and clinical trials become more complex. eClinical Connect in Mainz, Germany (June 10): The first European installment will include half-day presentations, providing attendees with insight on future-ready data strategies, elluminate Clinical Data Cloud® adoption case studies presented by prominent Top 50 biopharma, and the eClinical Solutions vision and elluminate roadmap – including use cases for enabling clinical teams with robust data transformation tools. eClinical Connect in Paris, France (June 12): Later the same week in Europe, the Paris Connect's sessions and speakers will cover AI strategies, holistic approaches to risk-based quality management (RBQM), expanding clinical data platform use cases across an organization, and a CRO's experience streamlining data cleaning with a centralized data workbench. "With a massive technology reinvention upon us thanks to the growing power and priority level of AI, it was important for us to supplement distinguished industry events like DIA with additional forums for collaboration with our clients and other life sciences stakeholders to discuss the most effective clinical trial strategies and approaches," said Raj Indupuri, Co-founder and CEO at eClinical Solutions. "During this unprecedented time, we must carefully examine how to most effectively harness AI tools safely with trust to improve key industry pain points. We are proud to convene top minds in life sciences at our eClinical Connect events to not only discuss unlocking AI's potential across the clinical data lifecycle, but also dive into other pertinent topics including holistic RBQM and risk-based approaches to optimize cycle times and future-proof trials, ultimately delivering innovative therapies to patients faster." eClinical Solutions has also revealed details into this year's ENGAGE Annual Conference, which will be held October 29-30 in Philadelphia, Pennsylvania. The event will provide executives the opportunity to explore the latest advancements in AI-driven innovation, insight into risk-based strategies to optimize decision-making, and tactical ways teams can reduce cycle times and improve efficiency. To learn more about these events, including how you can register to attend, visit the eClinical Solutions website: About eClinical Solutions eClinical Solutions' industry-leading data & analytics platform, elluminate®, and biometrics services experts help biopharma researchers at large, mid-size, and emerging life sciences organizations manage trial complexity in less time and with fewer resources. Clients get accurate and timely data insights for better decision-making – enabling them to reduce cycle times, improve productivity, easily scale, and develop tomorrow's breakthroughs with today's resources. eClinical is a privately-held, purpose-driven company with a global workforce and winner of the 2025 Top Workplaces Culture Excellence Award, 2024 Top Workplaces USA Award, and Great Place To Work® India Certification™. Learn more at and follow eClinical Solutions on LinkedIn. View source version on Contacts Olivia MannioneClinical@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
Veolia partners with Jamestown, Rhode Island to provide high-quality water service
JAMESTOWN, R.I.--(BUSINESS WIRE)--Veolia North America, the leading provider of water services and environmental solutions in the U.S. and Canada, has entered a three-year agreement to operate the water treatment plant for the Town of Jamestown, Rhode Island, providing high standards of water quality and professional operation for nearly 1,600 homes and businesses in the coastal community. Leading provider of water services and environmental solutions in the U.S. and Canada enters a three-year agreement to operate the water treatment plant for Jamestown, Rhode Island Throughout the three-year contract, Veolia will provide a team of three certified, full-time professionals to operate Jamestown's plant, alleviating a staffing shortage that has become a perennial concern throughout the water sector. Veolia will provide a full contingent of certified employees to operate and maintain the water treatment plant, working in conjunction with municipal personnel to provide environmental security for the town and its residents. Jamestown's need for a deeper operational roster became apparent over a recent period when only one licensed individual was on hand to address the needs of the facility. In addition to dedicating Rhode Island-certified personnel specifically to operate the Jamestown Water Treatment Plant, Veolia has the ability to draw from its significant regional workforce to assist in meeting the facility's ever-evolving needs. Veolia will also provide opportunities for members of Jamestown's current bargaining union to attend training for water treatment operator licensing and advanced certifications, in an effort to cultivate a stronger municipal workforce for the water treatment plant. Upon mobilization in January of 2025, the Jamestown team and Veolia's support personnel wasted no time implementing effective and noticeable improvements to the facility and to water quality. Veolia's site leadership immediately identified a below-ground pump vault used for reading meters that was not appropriately structured for employees to enter it safely. In line with Veolia's non-negotiable emphasis on operational safety, site leaders installed electronic systems to take the required readings, then built a small structure with lights, handrails and rehabilitated stairs to reduce slip hazards and fall risks. Similar improvements to the plant's operating systems have resulted in immediate support for Jamestown's water quality. John Oatley, Regional Vice President for Veolia said: 'We are excited to work with the Town of Jamestown and provide the support this community deserves for the protection of both public and environmental health. Our team throughout Rhode Island and across New England has demonstrated efficiency, dedication and operational excellence. We look forward to bringing that to Jamestown and maintaining this unique area's remarkable quality of life.' Edward Mello, Jamestown Town Administrator said: 'The delivery of high-quality, safe drinking water to our residents is a paramount function of our local government services. Jamestown, like many communities, has struggled to recruit and retain qualified staff members in all areas of the services we provide. This partnership allows us the stability needed to continue this high-value service.' Veolia has a long-established reputation for high-quality operation of water and wastewater systems across southeastern New England, including facilities in Pawtucket and Woonsocket in Rhode Island, New London in Connecticut, Westborough in Massachusetts, and more. Veolia's service to the region exemplifies its global GreenUp strategy, striving to lead the ecological transformation of the planet by accelerating water quality improvement, hazardous waste treatment and disposal, decarbonization and technological innovation. A subsidiary of Veolia Group, Veolia North America (VNA) offers a full spectrum of water, waste and energy management services, including water and wastewater treatment, commercial and hazardous waste collection and disposal, energy consulting and resource recovery. VNA helps commercial, industrial, healthcare, higher education and municipality customers throughout North America. Headquartered in Boston, Mass., Veolia North America has more than 10,000 employees working at more than 350 locations across the continent. Veolia Group aims to become the benchmark company for ecological transformation. Present on five continents with 215,000 employees, the Group designs and deploys useful, practical solutions for the management of water, waste and energy that are contributing to a radical turnaround of the current situation. Through its three complementary activities, Veolia helps to develop access to resources, to preserve available resources and to renew them. In 2024, the Veolia group provided 111 million inhabitants with drinking water and 98 million with sanitation, produced 42 million megawatt hours of energy and treated 65 million tons of waste. Veolia Environnement (Paris Euronext: VIE) achieved consolidated revenue of 44.7 billion euros in 2024.
